Skip to main content
. 2021 Feb 4;21:115. doi: 10.1186/s12885-021-07818-4

Table 5.

The representative completed clinical trials about osteosarcoma

No. Study Title Conditions Interventions
1 Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated with HDMTX Osteosarcoma Drug: Calcium Folinate and [6R] 5,10-methylenetetrahydrofolate
2 Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma Osteosarcoma Drug: Cisplatin, Doxorubicin and Methotrexate
3 Glembatumumab Vedotin in Treating Patients with Recurrent or Refractory Osteosarcoma Recurrent Osteosarcoma

Drug: Glembatumumab Vedotin

Other: Laboratory Biomarker Analysis

And Pharmacological Study

4 Eribulin Mesylate in Treating Patients with Recurrent or Refractory Osteosarcoma Recurrent Osteosarcoma

Drug: Eribulin Mesylate

Other: Pharmacological Study

5 Chemotherapy for Patients with Osteosarcoma Osteosarcoma Drug: Pemetrexed
6 Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung Osteosarcoma Metastatic Drug: Cisplatin liposomal
7 Preventing Nephrotoxicity and Ototoxicity from Osteosarcoma Therapy Osteosarcoma Drug: Pantoprazole and High-dose methotrexate infusion duration
8 Inhaled Sargramostim in Treating Patients with First Pulmonary (Lung) Recurrence of Osteosarcoma

Metastatic Cancer

Sarcoma

Biological: sargramostim

Procedure: conventional surgery

9 Differentiation of Bone Sarcomas and Osteomyelitis with Ferumoxytol-Enhanced MRI

Bone Cancer

Osteosarcoma

Drug: Feraheme

Procedure: Magnetic Resonance Imaging (MRI) scan

10 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma Sarcoma Drug: Dacarbazine
11 A Study of Bevacizumab in Combination with Chemotherapy for Treatment of Osteosarcoma Osteosarcoma

Biological: Bevacizumab

Drug: Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, etoposide

Procedure: Surgery

Radiation: Radiotherapy

12 A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma Osteosarcoma Drug: Cyclophosphamide and Sirolimus
13 Samarium Sm 153 and Stem Cell Transplant Followed by Radiation Therapy Patients with Osteosarcoma Sarcoma

Biological: filgrastim

Drug: ifosfamide

Procedure: peripheral blood stem cell transplantation

Radiation: Sm-EDTMP (low dose) and Sm-EDTMP (higher dose)

14 Gemcitabine and Docetaxel in Treating Patients with Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Sarcoma

Biological: filgrastim and pegfilgrastim

Drug: docetaxel and gemcitabine hydrochloride

Genetic: microarray analysis

Other: laboratory biomarker analysis and pharmacokinetic study

15 Temsirolimus and Cixutumumab in Treating Patients with Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Metastatic Osteosarcoma Recurrent Osteosarcoma

Biological: Cixutumumab

Other: Laboratory Biomarker Analysis

Drug: Temsirolimus

16 Therapeutic Angiotensin-(1–7) in Treating Patients with Metastatic Sarcoma That Cannot Be Removed by Surgery

Bone Cancer

Metastatic Osteosarcoma

Drug: therapeutic angiotensin-(1–7)

Other: laboratory biomarker analysis

17 Sorafenib in Treating Patients with Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)

Metastatic Osteosarcoma

Recurrent Osteosarcoma

Drug: sorafenib tosylate

Procedure: therapeutic conventional surgery, computed tomography and dynamic contrast-enhanced magnetic resonance imaging

Other: laboratory biomarker analysis and pharmacological study

18 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients with Recurrent Sarcoma Sarcoma Drug: temsirolimus plus liposomal doxorubicin
19 A Study of Pemetrexed in Children with Recurrent Cancer Osteosarcoma Drug: pemetrexed
20 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients with Advanced or Metastatic Sarcoma Metastatic Osteosarcoma Recurrent Osteosarcoma

Drug: Gamma-Secretase Inhibitor RO4929097 and Vismodegib

Other: Laboratory Biomarker Analysis and Pharmacological Study

21 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients with Recurrent/ Refractory Solid Tumors

Osteogenic

Sarcoma

Drug: nab-paclitaxel
22 Cixutumumab and Temsirolimus in Treating Younger Patients with Recurrent or Refractory Sarcoma Recurrent Osteosarcoma

Biological: Cixutumumab

Other: Laboratory Biomarker Analysis

Drug: Temsirolimus

23 Cixutumumab in Treating Patients with Relapsed or Refractory Solid Tumors Recurrent Osteosarcoma

Biological: cixutumumab

Other: laboratory biomarker analysis

24 Alisertib in Treating Young Patients with Recurrent or Refractory Solid Tumors or Leukemia Recurrent Osteosarcoma

Drug: Alisertib

Other: Laboratory Biomarker Analysis and Pharmacological Study

25 Depsipeptide (Romidepsin) in Treating Patients with Metastatic or Unresectable Soft Tissue Sarcoma Adult Extraskeletal Osteosarcoma Drug: romidepsin
26 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

Relapsed Ewing Sarcoma

Refractory Ewing Sarcoma

Drug: Linsitinib
27 Olaparib in Adults with Recurrent/Metastatic Ewing’s Sarcoma Ewing’s Sarcoma Drug: Olaparib
28 Cytarabine in Treating Young Patients with Recurrent or Refractory Ewing’s Sarcoma Sarcoma Drug: cytarabine
29 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients with Newly-Diagnosed Metastatic Ewing’s Sarcoma Family of Tumors Sarcoma

Drug: celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, MESNA and Filgrastim

Procedure: conventional surgery

Radiation: radiation therapy

30 Sunitinib in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Sarcoma Drug: sunitinib malate
31 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide with or Without Bevacizumab in Treating Young Patients with Refractory or First Recurrent Extracranial Ewing Sarcoma Ewing Sarcoma of Bone

Drug: topotecan hydrochloride, vincristine sulfate and cyclophosphamide

Biological: bevacizumab

32 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients with Relapsed/Refractory Ewing’s Sarcoma and Neuroblastoma

Neuroblastoma

Sarcoma

Drug: Cyclophosphamide, Topotecan, and Bevacizumab
33 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Ewing’s Sarcoma Biological: IMC-A12 (cixutumumab)
34 Trial of Dasatinib in Advanced Sarcomas Sarcoma, Ewing’s Drug: Dasatinib
35 Trabectedin in Treating Young Patients with Recurrent or Refractory Soft Tissue Sarcoma or Ewing’s Family of Tumors Recurrent Ewing Sarcoma

Drug: trabectedin

Other: pharmacological study

36 A Pilot Study of Autologous T-Cell Transplantation with Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

Ewing’s Sarcoma

Rhabdomyosarcoma

Biological: therapeutic autologous dendritic cells

Drug: indinavir sulfate

Procedure: peripheral blood stem cell transplantation

37 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients with Sarcoma Sarcoma

Biological: filgrastim

Drug: cisplatin, doxorubicin hydrochloride, ifosfamide and melphalan

Procedure: peripheral blood stem cell transplantation

38 Study Of CP-751,871 In Patients with Ewing’s Sarcoma Family of Tumors Ewing’s Sarcoma Drug: CP-751,871
39 Arsenic Trioxide in Treating Patients with Advanced Neuroblastoma or Other Childhood Solid Tumors Sarcoma Drug: arsenic trioxide
40 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma Adult Medulloblastoma

Radiation: radiation therapy

Drug: temozolomide and plerixafor

Other: laboratory biomarker analysis and pharmacological study

41 Therapy to Treat Ewing’s Sarcoma, Rhabdomyosarcoma or Neuroblastoma Sarcoma

Drug: Tumor Purged/CD25 Depleted Lymphocytes and rhIL-7

Biological: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine and Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine